Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd., Mailstop H17-2, Atlanta, GA30333, USA.
J Antimicrob Chemother. 2021 May 12;76(6):1495-1497. doi: 10.1093/jac/dkab052.
Nikkomycin Z is a competitive inhibitor of chitin synthase-an enzyme needed for synthesis of the fungal cell wall. Nikkomycin Z shows promise as a treatment for coccidioidomycoses and mixed activity has been described against other fungi and yeast. To our knowledge, it has not previously been tested against the emerging fungal pathogen Candida auris.
To determine the in vitro activity of nikkomycin Z against C. auris.
Nikkomycin Z was tested by broth microdilution against a panel of 100 isolates of genetically diverse C. auris from around the world.
Nikkomycin Z showed mixed activity against the tested isolates, with an MIC range of 0.125 to >64 mg/L. The MIC50 and MIC90 were 2 and 32 mg/L, respectively.
These findings suggest nikkomycin Z has in vitro activity against some, but not all isolates of C. auris.
尼可霉素 Z 是几丁质合成酶的竞争性抑制剂，几丁质合成酶是真菌细胞壁合成所必需的酶。尼可霉素 Z 有望成为治疗球孢子菌病的一种药物，并且对其他真菌和酵母具有混合活性。据我们所知，它以前尚未针对新兴的真菌病原体耳念珠菌进行过测试。
确定尼可霉素 Z 对耳念珠菌的体外活性。
通过肉汤微量稀释法对来自世界各地的 100 株遗传多样性的耳念珠菌进行了尼可霉素 Z 的测试。
尼可霉素 Z 对测试的分离株表现出混合活性，MIC 范围为 0.125 至>64mg/L。MIC50 和 MIC90 分别为 2 和 32mg/L。
这些发现表明尼可霉素 Z 对某些，但不是所有的耳念珠菌分离株具有体外活性。
